Relevant bibliographies by topics / Yellow fever, prevention

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Yellow fever, prevention'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Yellow fever, prevention.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Yellow fever, prevention"

1

Barnett, E. D. "Yellow Fever: Epidemiology and Prevention." Clinical Infectious Diseases 44, no. 6 (March 15, 2007): 850–56. http://dx.doi.org/10.1086/511869.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ribeiro Junior, Marcelo Augusto Fontanelle, Vinicius Cunha Rodrigues, Celia Ya Dan Feng, Alexander Trong Minh Nguyen, Giovana El Khouri Bechara, and Raíssa Reis de Moura. "Yellow Fever." Revista de Medicina 97, no. 4 (December 18, 2018): 407–14. http://dx.doi.org/10.11606/issn.1679-9836.v97i4p407-414.

Full text
Abstract:
Since January 2017, there have been at least 1563 suspected cases of Yellow Fever, 629 confirmed cases and 232 confirmed deaths. Yellow fever is a viral hemorrhagic disease endemic to the tropical parts of Africa and South America. At the present time, it has presented a significant increase in its incidence in Brazil, with important repercussions and impacts on the public health. This review paper outlines the causes of yellow fever, as well as the disease epidemiology, progression, diagnosis, treatment and prevention. We conclude by reporting on the current epidemic in Brazil and future directions for research. Method: Data from Pubmed, SciELO, Medline and government sources concerning Yellow Fever were used, dating from 2002 to 2018. In the collection of the data the following descriptors were used: Yellow-fever, Aedes, Arbovirus and Flavivirus.
APA, Harvard, Vancouver, ISO, and other styles
3

Reno, Elaine, Nicolas G. Quan, Carlos Franco-Paredes, Daniel B. Chastain, Lakshmi Chauhan, Alfonso J. Rodriguez-Morales, and Andrés F. Henao-Martínez. "Prevention of yellow fever in travellers: an update." Lancet Infectious Diseases 20, no. 6 (June 2020): e129-e137. http://dx.doi.org/10.1016/s1473-3099(20)30170-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Stephenson, J. R. "Prevention and control of yellow fever in Africa." Vaccine 5, no. 3 (September 1987): 253–54. http://dx.doi.org/10.1016/0264-410x(87)90138-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stovba, L. F., V. T. Krotkov, S. A. Melnikov, D. I. Paveliev, N. K. Chernikova, and S. V. Borisevich. "Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections." Journal of microbiology, epidemiology and immunobiology 98, no. 5 (November 2, 2021): 579–87. http://dx.doi.org/10.36233/0372-9311-102.

Full text
Abstract:
Epidemic vector-borne viral infections pose a serious threat to public health worldwide. There is currently no specific preventive treatment for most of them. One of the promising solutions for combating viral fevers is development of vector vaccines, including MVA-based vaccines, which have virtually no adverse side effects. The safety of the MVA strain and absent reactogenicity of recombinant MVA vaccines have been supported by many clinical trials.The article focuses on test results for similar preventive products against viral fevers: Crimean-Congo hemorrhagic fever, Rift Valley fever, yellow fever, Chikungunya and Zika fevers.Their immunogenicity was evaluated on immunocompetent and immunocompromised white mice; their protective efficacy was assessed on immunocompromised white mice deficient in IFN-α/β receptors, that are used for experimental modeling of the infection. Nearly all the new recombinant vaccines expressing immunodominant antigens demonstrated 100% protective efficacy. It has been found that although the vaccine expressing Zika virus structural proteins induced antibodies against specific viral glycoproteins, it can be associated with high risks when used for prevention of Zika fever in individuals who had dengue fever in the past, due to the phenomenon known as antibody-dependent enhancement of infection, which can occur in diseases caused by antigenically related flaviruses. For this reason, the vaccine expressing non-structural protein 1 (NS1) was developed for vaccination against Zika fever.The yellow fever vaccine developed on the MVA platform had immunogenicity similar to that of the commercial 17D vaccine, outperforming the latter in safety.
APA, Harvard, Vancouver, ISO, and other styles
6

Handari, Bevina D., Dipo Aldila, Bunga O. Dewi, Hanna Rosuliyana, and Sarbaz H. A. Khosnaw. "Analysis of yellow fever prevention strategy from the perspective of mathematical model and cost-effectiveness analysis." Mathematical Biosciences and Engineering 19, no. 2 (2021): 1786–824. http://dx.doi.org/10.3934/mbe.2022084.

Full text
Abstract:
<abstract><p>We developed a new mathematical model for yellow fever under three types of intervention strategies: vaccination, hospitalization, and fumigation. Additionally, the side effects of the yellow fever vaccine were also considered in our model. To analyze the best intervention strategies, we constructed our model as an optimal control model. The stability of the equilibrium points and basic reproduction number of the model are presented. Our model indicates that when yellow fever becomes endemic or disappears from the population, it depends on the value of the basic reproduction number, whether it larger or smaller than one. Using the Pontryagin maximum principle, we characterized our optimal control problem. From numerical experiments, we show that the optimal levels of each control must be justified, depending on the strategies chosen to optimally control the spread of yellow fever.</p></abstract>
APA, Harvard, Vancouver, ISO, and other styles
7

Tomashek, Kay M., Mark Challberg, Seema U. Nayak, and Helen F. Schiltz. "Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?" Vaccines 7, no. 4 (November 8, 2019): 179. http://dx.doi.org/10.3390/vaccines7040179.

Full text
Abstract:
Yellow fever is a potentially fatal, mosquito-borne viral disease that appears to be experiencing a resurgence in endemic areas in Africa and South America and spreading to non-endemic areas despite an effective vaccine. This trend has increased the level of concern about the disease and the potential for importation to areas in Asia with ecological conditions that can sustain yellow fever virus transmission. In this article, we provide a broad overview of yellow fever burden of disease, natural history, treatment, vaccine, prevention and control initiatives, and vaccine and therapeutic agent development efforts.
APA, Harvard, Vancouver, ISO, and other styles
8

Monath, Thomas P., and Martin S. Cetron. "Prevention of Yellow Fever in Persons Traveling to the Tropics." Clinical Infectious Diseases 34, no. 10 (May 15, 2002): 1369–78. http://dx.doi.org/10.1086/340104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Avelino-Silva, Vivian Iida, Hilario Sousa Francelino, and Esper Georges Kallás. "YELLOW FEVER PREVENTION STRATEGIES AWARENESS AMONG HIV-INFECTED PATIENTS IN SÃO PAULO, BRAZIL." Revista do Instituto de Medicina Tropical de São Paulo 56, no. 5 (September 2014): 417–20. http://dx.doi.org/10.1590/s0036-46652014000500008.

Full text
Abstract:
Introduction: Vaccination is the main preventive strategy against Yellow Fever (YF), which is a public health concern in Brazil. However, HIV-infected patients might have insufficient knowledge regarding YF, YF prevention, and vaccines in general. Methods: In this questionnaire-based study, data from 158 HIV-infected individuals were addressed in three distinct outpatient clinics in São Paulo. Information was collected on demographic and clinical characteristics, as well as patients' knowledge of vaccines, YF and YF preventive strategies. In addition, individual YF vaccine recommendations and vaccine status were investigated. Results: Although most participants adequately ascertain the vaccine as the main prevention strategy against YF, few participants were aware of the severity and lack of specific treatment for YF. Discrepancy in YF vaccine (patients who should have taken the vaccine, but did not) was observed in 18.8% of participants. Conclusion: YF is an important and preventable public health concern, and these results demonstrate that more information is necessary for the HIV-infected population.
APA, Harvard, Vancouver, ISO, and other styles
10

Lima, Maura Antonia, Nicolina Silvana Romano-Lieber, and Ana Maria Ribeiro de Castro Duarte. "Circulation of antibodies against yellow fever virus in a simian population in the area of Porto Primavera Hydroelectric Plant, São Paulo, Brazil." Revista do Instituto de Medicina Tropical de São Paulo 52, no. 1 (February 2010): 11–16. http://dx.doi.org/10.1590/s0036-46652010000100002.

Full text
Abstract:
Yellow fever (YF) is an acute viral infectious disease transmitted by mosquitoes which occurs in two distinct epidemiological cycles: sylvatic and urban. In the sylvatic cycle, the virus is maintained by monkey's infection and transovarian transmission in vectors. Surveillance of non-human primates is required for the detection of viral circulation during epizootics, and for the identification of unaffected or transition areas. An ELISA (enzyme-linked immunosorbent assay) was standardized for estimation of the prevalence of IgG antibodies against yellow fever virus in monkey sera (Alouatta caraya) from the reservoir area of Porto Primavera Hydroelectric Plant, in the state of São Paulo, Brazil. A total of 570 monkey sera samples were tested and none was reactive to antibodies against yellow fever virus. The results corroborate the epidemiology of yellow fever in the area. Even though it is considered a transition area, there were no reports to date of epizootics or yellow fever outbreaks in humans. Also, entomological investigations did not detect the presence of vectors of this arbovirus infection. ELISA proved to be fast, sensitive, an adequate assay, and an instrument for active search in the epidemiological surveillance of yellow fever allowing the implementation of prevention actions, even before the occurrence of epizootics.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Yellow fever, prevention"

1

DELFINO, Denizard André de Abreu. "Investigação epidemiológica de epizootia de febre amarela em primatas não-humanos em Goiás, no período de 2007 a 2010." Universidade Federal de Goiás, 2011. http://repositorio.bc.ufg.br/tede/handle/tde/849.

Full text
Abstract:
Made available in DSpace on 2014-07-29T15:07:32Z (GMT). No. of bitstreams: 1 Dissertacao Denizard Andre de Abreu Delfino.pdf: 922702 bytes, checksum: f27146bc0b024ae0d79c5f4cfec679f6 (MD5) Previous issue date: 2011-03-30
The objective of this study was to carry out and analyze the actions taken to control the yellow fever epizootic in non-human primates, recorded in November 2007 to March 2010 in Aparecida de Goiania, Goias Brazil. The primary epidemiological information on the disease was obtained from the Municipal Health Secretariat, by the local Center for Zoonosis Control. Data were analyzed from the outbreak reports. In A descriptive study, the control actions, such as blocking vaccine against yellow fever by the municipal health department and the evaluation of physical barriers to contain the virus, were verified. The inspection of 58 dead nonhuman primates, representing 100% of the animals found in the period previously mentioned, was used. From these, 34.48% (20/58) were able to have samples collected, according to the specifications of the Epizooty Handbook Of this amount (58), 27.59% (16/58) of monkeys were collected and3.45% (2/58) presented positivity for yellow fever virus. By evaluating the actions that contributed to the epidemiological assessment at the city, it is emphasized the occurrence of three deaths among genera and species of nonhuman primates, Alouatta caraya, Cebus apella and Callithrix spp, with the circulation of yellow fever virus in two cities with epidemiological distinct characteristics. The areas which showed the highest incidence of deaths of monkeys had also the greatest degree of urban growth, characterized by recent environmental changes and residual maintenance of natural areas.
O presente estudo constituiu na condução e análises de ações desenvolvidas no controle da epizootia de febre amarela em primatas não-humanos, registrada nos meses de novembro 2007 a março de 2010 em Aparecida de Goiânia, Goiás. As informações epidemiológicas primárias relativas à enfermidade foram obtidas junto à Secretaria Municipal de Saúde, pelo Centro de Controle de Zoonoses local. A partir das fichas de notificação para epizootia os dados foram analisados. Foi realizado estudo descritivo, que estudou as ações de controle, como bloqueio vacinal contra a FA pela secretaria municipal de saúde do município e a avaliação das barreiras físicas na contenção do vírus amarílico. Foi utilizada a inspeção de 58 primatas não-humanos mortos, que representaram 100% dos animais encontrados no período acima citado, sendo que destes 34,48% (20/58) estavam aptos para colheita de amostras, segundo as especificações do com o Manual de Epizootia. Deste montante, foram coletados 27,59% (16/58) de macacos, com uma positividade para o vírus amarílico de 3,45% (2/58). Avaliando as ações que contribuíram para realização da investigação epidemiológica no município, destaca-se que ocorreram mortes entre três gêneros e espécies de primatas não-humanos, Alouatta caraya, Cebus spp. e Callithrix spp., com a circulação do vírus da FA em duas localidades com características epidemiológicas distintas. As áreas de maior ocorrência de mortes de macacos foram aquelas com maior grau de antropização, caracterizadas por alterações ambientais recentes e manutenção residual de áreas naturais.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Yellow fever, prevention"

1

1955-, Humphreys Margaret, ed. Yellow fever and the South. New Brunswick: Rutgers University Press, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

World Health Organization. Expanded Programme on Immunization. The resurgence of deadly yellow fever: Prevention using EPI : highlights. Geneva: World Health Organization, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Coelho, Benedito Carlos Marcondes. O pacote da saúde no Governo de Rodrigues Alves, 1902-1906. [São Paulo?: s.n., 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fiebre dorada o fiebre amarilla?: La Fundación Rockefeller en México (1911-1924). Guadalajara, México: Universidad de Guadalajara, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

In the interest of truth: The life and science of Surgeon General George Miller Sternberg. Fort Sam Houston, TX: Office of The Surgeon General, Borden Institute, U.S. Army Medical Department Center and School, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Parker, James N., and Philip M. Parker. Yellow fever: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Monath, Thomas P., and J. Erin Staples. Yellow fever. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198570028.003.0045.

Full text
Abstract:
Yellow fever is an acute mosquito-borne flavivirus infection characterized in its full-blown form by fever, jaundice, albuminuria, and haemorrhage. Two forms are distinguished: urban yellow fever in which the virus is spread from person to person by peridomestic Aedes aegypti mosquitoes and jungle (sylvan) yellow fever transmitted by tree-hole breeding mosquitoes between non-human primates and sometimes humans. Yellow fever is endemic and epidemic in tropical areas of the Americas and Africa but has never appeared in Asia or the Pacific region. Prevention and control are effected principally through yellow fever vaccination.
APA, Harvard, Vancouver, ISO, and other styles
8

Organization, World Health, ed. Prevention and control of yellow fever in Africa. Geneva: World Health Organization, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

(WHO), World Health Organization. Control of Yellow Fever: Field Guide (PAHO Scientific Publications). Not Avail, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yellow Fever and the South. The Johns Hopkins University Press, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Yellow fever, prevention"

1

Song, Alice Tung Wan, and Luiz Augusto Carneiro D’Albuquerque. "Yellow Fever: Prevention in Transplant Candidates and Emerging Treatment Data for Liver Transplant." In Emerging Transplant Infections, 1–16. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-01751-4_41-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Song, Alice Tung Wan, and Luiz Augusto Carneiro D’Albuquerque. "Yellow Fever: Prevention in Transplant Candidates and Emerging Treatment Data for Liver Transplant." In Emerging Transplant Infections, 1011–26. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-25869-6_41.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"One. “A Beautiful Spot for a Grave”: Prophylaxis and Prevention in the Slave-Trade Contact Zones." In The Yellow Demon of Fever, 27–61. Yale University Press, 2020. http://dx.doi.org/10.12987/9780300252019-003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kılıç, Orhan. "Pandemics Throughout Historyand Their Effects on Society Life." In Reflections on the Pandemic in the Future of the World, 13–53. Turkish Academy of Sciences, 2020. http://dx.doi.org/10.53478/tuba.2020.026.

Full text
Abstract:
One of the important factors to be considered in the explanation and interpretation of history is pandemic diseases. The nature of the pandemic diseases, ways of prevention and treatments are not fully known for a long time. People saw the disease as a wrath of God until they learned the nature of the epidemic, and often placed a blessing on it. Many diseases with an endemic, epidemic and pandemic character have been experienced since ancient times and millions of people have died in these outbreaks. Plague, malaria, cholera, yellow fever, smallpox, influenza, tuberculosis, typhoid, typhus and syphilis are important epidemic diseases that cause mass death. However, all of these could not produce outbreaks while would affect several continents of the world. We can only say that plague, cholera and influenza diseases are pandemic epidemics and that affect people globally known. The world has experienced from antiquity to the present, more than ten influenza pandemics with three plagues, seven cholera, and the outbreak we are experiencing today. Epidemic outbreaks of smallpox, malaria and yellow fever which caused the death of many people, were at least as effective as these three diseases.The reason for the high destruction of all pandemics is that the disease is not fully recognized. Therefore, the mortality rates were high, and the spreading areas were wide. Epidemics/pandemics deeply affected social life economically, socially, psychologically, culturally, politically, religiously, geographically and many more.
APA, Harvard, Vancouver, ISO, and other styles
5

Crawford, Dorothy H. "10. Viruses past, present, and future." In Viruses: A Very Short Introduction, 126–32. Oxford University Press, 2018. http://dx.doi.org/10.1093/actrade/9780198811718.003.0011.

Full text
Abstract:
‘Viruses past, present, and future’ looks at the changing pattern of virus infections through the ages and speculates about how humans and viruses might interact in the future. Viruses, such as smallpox and yellow fever, have debilitated populations across the globe throughout history. New research technologies will allow a greater number of ‘new’ viruses to be identified, leading to preventive vaccines and novel treatments. However, we may also face potential man-made virus threats from biological weapons of mass destruction to the unwitting promotion of pathogenic viruses, possibly through xenotransplantation, immune-suppressed chemotherapy patients, or viruses escaping from laboratories due to poor safety measures.
APA, Harvard, Vancouver, ISO, and other styles
6

Li, Jie Jack. "Sofosbuvir (Sovaldi)." In Top Drugs. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780199362585.003.0017.

Full text
Abstract:
Viruses are humanity’s invisible enemy. They wreak daily havoc by causing the flu, measles, rabies, hepatitis, smallpox, polio, and even human immunodeficiency virus (HIV). Although viruses have existed on the earth much longer than humans, it was not until in 1892 when the concept of virus took root when Chamberland experimented with viruses using the Pasteur–Chamberland filter. Solid evidence emerged when tobacco mosaic virus (TMV) crystal was isolated in 1935. However, human ingenuity afforded successful measures to combat viruses long before 1892. For instance, Jenner successfully pioneered a vaccination for preventing smallpox in 1796, nearly one hundred years before Chamberland’s exploits and before Pasteur developed the first vaccination for rabies in 1885. The scourge of polio has been nearly wiped out thanks to Salk’s inactivated polio vaccine (IPV) available since 1954 and Sabin’s oral poliovirus vaccine (OPV) popularized in 1960. The 1951 the Nobel Prize in Physiology or Medicine was awarded to Theiler for his contributions to yellow fever vaccines. In terms of small molecule antiviral drugs, the nucleoside iododeoxyuridine (IDU, 2), a simple analog of thymidine (3), was first synthesized and used as an antiviral drug in 1959 by Prusoff. Unfortunately, due to its systemic cardiotoxicities, IDU is now only used topically to treat herpes simplex keratitis. A similar antiviral nucleoside, trifluorothymidine (TFT, Viroptic, 4), is less toxic than 2, and is also primarily used topically in eyes to kill the herpes simplex virus (HSV). Under the leadership of future Nobel laureate Elion, Burroughs Wellcome introduced the nucleoside analog acyclovir (Zovirax, 5) in 1978 for the treatment of HSV infection.3 While not the first antiviral agent on the market, Zovirax (5) was the first small molecule drug to be widely used to control a viral infection. Introduction of valacyclovir (Valtrex, 6), a prodrug of Zovirax (5) with higher oral bioavailability, afforded the patient a more convenient regimen because it does not have to be taken as frequently as the parent drug Zovirax (5).
APA, Harvard, Vancouver, ISO, and other styles
7

Berg, Jessica W., Paul S. Appelbaum, Charles W. Lidz, and Lisa S. Parker. "The Independent Evolution of Informed Consent to Research." In Informed Consent. Oxford University Press, 2001. http://dx.doi.org/10.1093/oso/9780195126778.003.0020.

Full text
Abstract:
Despite apparent similarities in the issues raised, informed consent in the research setting has evolved quite separately from informed consent to treatment. Consent to treatment is largely a creature of case law, with some subsequent statutory modification. Consent to research has been shaped by professional codes, statutes, and administrative regulations, with the courts playing a less important role. Systematic medical research, of course, is a newer phenomenon than medical treatment. The eighteenth century saw some of the first efforts to demonstrate the etiology of diseases. One was Lind’s controlled study of the effects of citrus juices in preventing scurvy (1). Pierre Louis’s classic study, in the 1820s, of the efficacy of bloodletting as a treatment for pneumonia demonstrated the potential of clinical investigation, but his medical colleagues were slow to follow his lead (2). By the turn of the century, the pace of experimentation with human subjects was quickening. The etiologies of beriberi and pellagra, for example, were discovered using human volunteers. In the early years of systematic medical investigation, only sporadic attention was paid to the circumstances under which research should be carried out, including the issue of consent. There are a few statements from leading physicians of the time, such as Paul Ehrlich and William Osier, endorsing the disclosure of information about the risks and benefits of experimental treatment. After a public scandal in Prussia in the 1890s, involving experimentation on unsuspecting patients who were inoculated with the spirochete that causes syphilis, the Prussian government required consent for any further research with human subjects (3). Shortly thereafter, Walter Reed, conducting his famous experiments in Cuba on yellow fever, developed a contract—very much like the modern consent form— for his volunteers to sign, which included a discussion of the risks they would be running (3). Public concern in Germany culminated in the 1931 promulgation of guidelines that required clear explanations of innovative or experimental treatments (4). Interestingly, this pre-war German code of ethics, which addressed human experimentation, was, in some ways, more extensive in its protections and principles than either the post-war Nuremberg Code or Helsinki Declaration (5).
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Yellow fever, prevention"

1

Rossi, Lucas, André Backes, and Jefferson Souza. "Rain Gutter Detection in Aerial Images for Aedes aegypti Mosquito Prevention." In Workshop de Visão Computacional. Sociedade Brasileira de Computação - SBC, 2020. http://dx.doi.org/10.5753/wvc.2020.13474.

Full text
Abstract:
The detection of Aedes aegypti mosquito is essential in the prevention process of serious diseases such as dengue, yellow fever, chikungunya, and Zika virus. Common approaches consist of surveillance agents who need to enter residences to find and eliminate these outbreaks, but often they are unable to do this work due to the absence or resistance of the resident. This paper proposes an automatic system that uses aerial images obtained through a camera coupled from an Unmanned Aerial Vehicle (UAV) to identify rain gutters from a shed that may be mosquitoes’ foci. We use Digital Image Processing (DIP) techniques to differentiate the objects that may or may not be those foci of the mosquito-breeding. The experimental results show that the system is capable of automatically detecting the appropriately mosquito-breeding location.
APA, Harvard, Vancouver, ISO, and other styles
2

Tareq HAMMOODI, Zeyad. "CORONA EPIDEMIC (COVD 19) BETWEEN SHARIA AND MEDICINE." In International Research Congress of Contemporary Studies in Social Sciences (Rimar Congress 2). Rimar Academy, 2021. http://dx.doi.org/10.47832/rimarcongress2-7.

Full text
Abstract:
The Corona epidemic is a wide group of viruses that include viruses that can cause a group of illnesses in humans, ranging from the common cold to severe acute respiratory syndrome, as there is no definitive and specific treatment for the epidemic. The medicines used are helpful and supportive, and they mostly aim to reduce the patient’s temperature with the use of pulmonary resuscitation devices, as the body’s resistance depends on autoimmunity, as it is the main factor in preventing this epidemic, and here we must know the role of medical and forensic scholars in preventing and treating With what appears from this epidemic and other epidemics, we do not know when and how they will appear to the world. The emergence of this disease is an extension of several diseases before it and the so-called (contemporary diseases), which are contagious communicable diseases, including bird flonza disease, swine flonza, sass and AIDS, mad cow disease, Ebola, human papillomavirus, herpes simplex virus, yellow fever, and many others These diseases are epidemic.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Yellow fever, prevention' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography